X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Trichomylin
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Aureuspharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 27, 2021
Details:
Under the agreement, ZYUS’ cannabinoid formulations are expected to hit the Portuguese market as early as the second half of 2021. It's lead drug product candidate, Trichomylin® for pain management in a limited number of patients with osteoarthritis.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
News Type
